

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on March 18, 2002

3/18/02  
Date

Pat Jones  
Signature

TECH CENTER 1600/2900

APR 1 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

BANKIEWICZ et al.

Serial No.: 09/887,854

Filing Date: June 21, 2001

Title: CONVECTION-ENHANCED DELIVERY OF AAV VECTORS



Group Art Unit: 1633

Examiner: Unassigned

RECEIVED

APR 29 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The information listed below may be material to the examination of the above-identified application. Copies of the information and completed PTO-1449 forms are submitted herewith. The Examiner is respectfully requested to make this information of official record in the application. All references not previously of record in related application serial number 09/320,171 from which the present application claims priority under 35 U.S.C. §120 are being submitted herewith. Thus, pursuant to C.F.R. §1.98(d), copies of the references are not included. The information includes:

United States Patent No. 5,139,941 issued August 18, 1992, to Muzyczka et al;  
United States Patent No. 5,173,414 issued Dec. 22, 1992, to Lebkowski et al.;  
United States Patent No. 5,399,346 issued March 21, 1995 to Anderson et al.;  
United States Patent No. 5,677,158 issued October 14, 1997, to Zhou et al.;  
United States Patent No. 5,720,720 issued February 24, 1998 to Laske et al.;

United States Patent No. 6,103,226 issued August 15, 2000 to Kang et al.;  
United States Patent No. 6,180,613 issued January 30, 2001 to Kaplitt et al.;  
International Publication No. WO 95/05864, published March 2, 1995;  
International Publication No. WO 95/28493, published October 26, 1995;  
International Publication No. WO 95/34670, published December 21, 1995;  
International Publication No. WO 97/17458, published May 15, 1997;  
International Publication No. WO 98/00014, published January 8, 1998;  
German Patent Application No. DE 3841955 A1, July 13, 1989;  
Patent Abstracts of Japan vol. 013, No. 328 (C-621), July 24, 1989;  
Bankiewicz et al., "Practical Aspects of the Development of *ex Vivo* and *in Vivo*  
Gene Therapy for Parkinson's Disease," *Experimental Neurology* 144:147-156 (1997);  
Bankiewicz et al., "Application of Gene Therapy for Parkinson's Disease:  
Nonhuman Primate Experience," *Advances in Pharmacology* 42:801-806 (1998);  
Brynes et al., "Immunological Instability of Persistent Adenovirus Vectors in the  
Brain: Peripheral Exposure to Vector Leads to Renewed Inflammation, Reduced Gene  
Expression, and Demyelination," *Journal of Neuroscience* 16(9):3045-3055 (1996);  
Carter, B.J., "Adeno-Associated Virus Vectors," *Current Opinion in  
Biotechnology* 3:533-539 (1992);  
Conrad et al., "Safety of Single-Dose Administration of an Adeno-Associated  
Virus (AAV)-CFTR Vector in the Primate Lung," *Gene Therapy* 3:658-668 (1996);  
During et al., "*In Vivo* Expression of Therapeutic Human Genes for Dopamine  
Production in the Caudates of MPTP-Treated Monkey's Using an AAV Vector," *Gene  
Therapy* 5:820-827 (1998);  
Eberling et al., "A Novel MPTP Primate Model of Parkinson's Disease:  
Neurochemical and Clinical Changes," *Brain Research* 805:259-262 (1998);  
Edge et al., "Total Synthesis of a Human Leukocyte Interferon Gene," *Nature*  
292:756-762 (1981);  
Fan et al., "Behavioral Recovery in 6-Hydroxydopamine-Lesioned Rats by  
Cotransduction of Striatum with Tyrosine Hydroxylase and Aromatic L-Amino Acid

Decarboxylase Genes Using Two Separate Adeno-Associated Virus Vectors," *Human Gene Therapy* 9:2527-2535 (1998);

Flotte et al., "Stable *In Vivo* Expression of the Cystic Fibrosis Transmembrane Conductance Regulator With an Adeno-Associated Virus Vector," *Proc. Natl. Acad. Sci. USA* 90:10613-10617 (1993);

Graham et al., "Characteristic of a Human Cell Line Transformed by DNA From Human Adenovirus Type 5," *J. Gen Virol.* 36:59-72 (1977);

Herzog et al., "Long-Term Correction of Canine Hemophilia B by Gene Transfer of Blood Coagulation Factor IX Mediated By Adeno-Associated Viral Vector," *Nature Medicine* 5:56-63 (1999);

Kaplitt et al., "Long-Term Gene Expression and Phenotypic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain," *Nature Genetics* 8:148-153 (1994);

Kaplitt et al., "Transfer and Expression of Potentially Therapeutic Genes into the Mammalian Central Nervous System *In Vivo* Using Adeno-Associated Viral Vectors," *Viral Vectors, Gene Therapy and Neuroscience Applications*, Kaplitt and Loewy eds., 12:193-210, Academic Press, San Diego (1995);

Kass-Eisler et al., "The Impact of Developmental Stage, Route of Administration and the Immune System on Adenovirus-Mediated Gene Transfer," *Gene Therapy* 1:395-402 (1994);

Kotin, R.M., "Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy," *Human Gene Therapy* 5:793-801 (1994);

Kroll et al., "Increasing Volume of Distribution to the Brain with Interstitial Infusion: Dose, Rather Than Convection, Might be the Most Important Factor," *Neurosurgery* 38(4):746-754 (1996);

Langston, J. William, "Mechanism of MPTP Toxicity: More Answers, More Questions," *Trends Pharmacol. Sci.* 6:375-378 (1985);

Leff et al., "Long-Term Restoration of Striatal L-Aromatic Amino Acid Decarboxylase Activity Using Recombinant Adeno-Associated Viral Vector Gene

Transfer in a Rodent Model of Parkinson's Disease," XP-000857456 *Neuroscience* 92(1):185-196 (1999);

Lyden et al., "Effect of Ischemic Cerebral Volume Changes on Behavior," *Behavioral Brain Research* 87:59-67 (1997);

Mandel et al., "Midbrain Injection of Recombinant Adeno-Associated Virus Encoding Rat Glial Cell Line-Derived Neurotrophic Factor Protects Nigral Neurons in a Progressive 6-Hydroxydopamine-Induced Degeneration Model of Parkinson's Disease in Rats," *Proc. Natl. Acad. Sci. USA* 94:14083-14088 (1997);

Mandel et al., "Characterization of Intrastriatal Recombinant Adeno-Associated Virus-Mediated Gene Transfer of Human Tyrosine Hydroxylase and Human GTP-Cyclohydrolase I in a Rat Model of Parkinson's Disease," *Journal of Neuroscience* 18(11):4271-4284 (1998);

Matsushita, T. et al., "Adeno-Associated Virus Vectors Can Be Efficiently Produced Without Helper Virus," *Gene Therapy* 5:938-945 (1998);

Mizuno et al., "Adeno-Associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjunction With Ganciclovir Administration," *Jpn. J. Cancer Res.* 89:76-80 (1998);

Muzyczka, "Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells," *Current Topics in Microbiol. and Immunol* 158:97-129 (1992);

Okada et al., "Gene Therapy Against an Experimental Glioma Using Adeno-Associated Virus Vectors," *Gene Therapy* 3:957-964 (1996);

Samulski et al., "A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised *In Vitro* and Its Use to Study Viral Replication," *Journal of Virology* 61(10):3096-3101 (1987);

Szczyepka et al., "Viral Gene Delivery Selectively Restores Feeding and Prevents Lethality of Dopamine-Deficient Mice," *Neuron* 22:167-178 (1999);

Yang et al., "Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-Infected Hepatocytes *In Vivo*," *Gene Therapy* 3:137-144 (1996); and

Yang et al., "Cellular Immunity to Viral Antigens Limits E1-Deleted Adenoviruses for Gene Therapy," *Proc. Natl. Acad. Sci. USA* 91:4407-4411 (1994).

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

Respectfully submitted,

Date: March 18, 2002

By: D. Pasternak  
Dahna S. Pasternak  
Registration No. 41,411

ROBINS & PASTERNAK LLP  
545 Middlefield Road, Suite 180  
Menlo Park, CA 94025  
Telephone: 650-325-7812  
Facsimile: 650-325-7823